TLR10 Antibody (3C10C5) [DyLight 594]
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-70343DL594
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Flow (Cell Surface), Flow Cytometry
Label
DyLight 594 (Excitation = 593 nm, Emission = 618 nm)
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # 3C10C5
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for TLR10 Antibody (3C10C5) [DyLight 594]
Immunogen
A partial recombinant protein containing amino acids 20-474 (extracellular domain) of human TLR10.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Applications for TLR10 Antibody (3C10C5) [DyLight 594]
Application
Recommended Usage
Flow (Cell Surface)
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: TLR10
Long Name
Toll-like Receptor 10
Alternate Names
CD290
Gene Symbol
TLR10
Additional TLR10 Products
Product Documents for TLR10 Antibody (3C10C5) [DyLight 594]
Product Specific Notices for TLR10 Antibody (3C10C5) [DyLight 594]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...